Reducing fracture risk in the oldest old: Aging and the effect of pharmaceutical interventions in osteoporosis

Aging Clinical and Experimental Research

Volumn 19, Issue 1, 2007, Pages 1-3

  Boonen, Steven ^a   Crepaldi, Gaetano ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bisphosphonate treatment; Fracture risk reduction; Osteoporosis; Stronium ranelate

Indexed keywords

ALENDRONIC ACID; CALCIUM; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

AGE DISTRIBUTION; AGED; BONE DENSITY; CLAVICLE FRACTURE; CLINICAL TRIAL; COMORBIDITY; DISABILITY; DISEASE SEVERITY; DRUG MECHANISM; EDITORIAL; FALLING; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HUMERUS FRACTURE; LONG TERM CARE; MORTALITY; NUTRITIONAL DEFICIENCY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PELVIS FRACTURE; QUALITY OF LIFE; RIB FRACTURE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WRIST FRACTURE;

EID: 34047238464     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03325203     Document Type: Editorial

References (17)

1. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195-202.
2. Melton LJ, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993; 3: 113-9.
3. Melton LJ, Thamer M, Ray NF, et al. Factors attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 16-23.
4. Ettinger MP. Aging bone and osteoporosis. Arch Intern Med 2003; 163: 2237-46.
5. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. New Engl J Med 2001; 344: 1434-41.
6. Boonen SJ, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782-9.
7. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Amer Geriatr Soc 2004; 52: 1832-9.
8. Seeman E, Vellas B, Benhamou CL, et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women aged eighty years and over. J Bone Miner Res 2006; 21: 1113-20.
9. Harris ST, Watts NB, Genant HK, et al., for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 1999; 282: 1344-52.
10. McClung MR, Guesens P, Miller PD, et al., for the Hip Intervention Program Study Group. Effect of risedronate on hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
11. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
12. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: Treatment Of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005; 90: 2816-22.
13. Seeman E, Vellas B, Benhamou CL, et al. Sustained 5-year vertebral and non-vertebral fracture risk reduction with strontium ranelate in elderly women with osteoporosis. Osteoporos Int 2006; 18: 1-13(OC39).
14. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13: 257-64.
15. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081-2.
16. Kanis JA, Dawson A, Oden A, et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356-61.
17. Jonsson B, Kanis J, Dawson A, et al. Effect and offset of effect of treatments from hip fracture on health outcomes. Osteoporos Int 1999; 10: 193-9.